Penbutolol

Mechanism of action:
Penbutolol is a non-selective β-blocker. The β₁, β₂, and β₃ receptors are all Gs protein-coupled receptors. Once activated, they stimulate adenylyl cyclase, increase cAMP concentration, and subsequently activate protein kinase A, leading to downstream cellular responses. Penbutolol blocks β₁ receptors on cardiomyocytes, suppressing Gs-cAMP signaling, reducing myocardial contractility, and thereby lowering cardiac output and blood pressure. In addition, Penbutolol also blocks β₂ receptors on peripheral blood vessels and bronchial smooth muscle, lowering cAMP levels and weakening smooth muscle relaxation, which may cause bronchoconstriction and increased peripheral vascular resistance.
Reference(s):
1. Maurer HH et al. (2004). Screening for library-assisted identification and fully validated quantification of 22 beta-blockers in blood plasma by liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization. J Chromatogr A.
2. Aguirre C et al. (1994). Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents. Cancer Chemother Pharmacol.
3. Hjorth S et al. (1992). (-)-Penbutolol as a blocker of central 5-HT1A receptor-mediated responses. Eur J Pharmacol.
